Latest Bioavailability Stories
BEND, Oregon, December 15 /PRNewswire/ -- Bend Research Inc. announced today that its clients may now reference a key safety file for HPMCAS, an excipient used in technologies developed by the firm to enhance the oral bioavailability of clients' low-solubility drugs. Bend Research clients may now reference a Type V Drug Master File (DMF) for HPMCAS for regulatory filings with the FDA, Bend Research officials said. "We're excited about this new development and know it will...
MIAMI, Sept. 11 /PRNewswire/ -- RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM). Two of the firm's most popular product offerings, Arthri-Zen...
BASKING RIDGE, N.J., Aug. 24 /PRNewswire/ -- Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system. The study is a double-blind, randomized, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics and...
Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced top-line results from its Phase I clinical trial of an oral formulation of picoplatin in patients with solid tumors showing that picoplatin achieves linear and dose-dependent plasma exposure when given orally. Poniard's randomized, open-label, dose-ranging Phase I study was conducted at clinical sites in the US. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of...
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced top-line results from its Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors showing that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route. The results demonstrated that exposure to orally administered picoplatin was linear at doses below 200 mg, and that...
Penwest Pharmaceuticals has initiated dosing in a Phase I clinical trial of PW 4153, a drug candidate for the treatment of the symptoms of Parkinson's disease. The purpose of the Phase I trial of PW 4153 is to assess the bioavailability and pharmacokinetic blood levels of Penwest's formulation of the drug in healthy volunteers. PW 4153 is an extended release reformulation of a marketed drug that is dosed multiple times a day. The goal of this formulation is to extend the dosing interval of...
Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design, announced today its launch as a new company focused on providing comprehensive and strategic drug delivery and design solutions for pharmaceutical and other bioactives companies worldwide. The company provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. Appian Labs is funded and managed by venture firm Emergent...
Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development. It is a potent prokinetic agent initially being developed for the treatment of mild-to-moderate gastroparesis. The Phase I study showed that TZP-102 has excellent oral bioavailability in man and is safe and...
